PREMIUM
PILAR PÉREZ
@pilar_pj
Madrid
Updated Tuesday, 6April2021-16: 36
Share on Facebook
Share on Twitter
Send by email
Two years ago Johanna Mercier landed at the American company Gilead.
Then, the current commercial director of biotechnology did not know that one of her first projects would be to "erase" the condition of many chronic patients who live with HIV.
A strategic alliance with another
big pharma,
Merck, will save it two years of research to ensure that with two pills or two pricks a year, HIV patients stop being so.
For EL MUNDO, Mercier makes a
Become Premium from € 1 the first month
Take advantage of this limited-time offer and access all web content
I love you
Are you already Premium?
Log in
Cancel whenever you want
Check the terms and conditions of the service
According to the criteria of The Trust Project
Know more